Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble r… Read more
Minerva Neurosciences Inc (NERV) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.084x
Based on the latest financial reports, Minerva Neurosciences Inc (NERV) has a cash flow conversion efficiency ratio of 0.084x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.92 Million) by net assets ($-34.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Minerva Neurosciences Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Minerva Neurosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Minerva Neurosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Minerva Neurosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wisekey International Holding AG
NASDAQ:WKEY
|
-0.128x |
|
NORSK TITANIUM NK-08
F:84F
|
N/A |
|
centrotherm international AG
F:CTNK
|
0.077x |
|
E&E Recycling
TWO:8440
|
0.023x |
|
HOFFMANN GR.CEM.TEC. 1-
F:0VW
|
N/A |
|
Bank Victoria International
JK:BVIC
|
0.016x |
|
S-Fuelcell co. Ltd
KQ:288620
|
-0.022x |
|
CrownHaitai Holdings Co Ltd Preference Shares
KO:005745
|
0.020x |
Annual Cash Flow Conversion Efficiency for Minerva Neurosciences Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Minerva Neurosciences Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-25.69 Million | $-19.55 Million | 0.761x | +46.46% |
| 2023-12-31 | $-28.46 Million | $-14.78 Million | 0.520x | -57.79% |
| 2022-12-31 | $-20.02 Million | $-24.65 Million | 1.231x | +139.90% |
| 2021-12-31 | $7.98 Million | $-24.60 Million | -3.085x | -380.29% |
| 2020-12-31 | $52.66 Million | $-33.82 Million | -0.642x | +58.92% |
| 2019-12-31 | $27.78 Million | $-43.43 Million | -1.563x | -236.48% |
| 2018-12-31 | $90.26 Million | $-41.94 Million | -0.465x | -2077.04% |
| 2017-12-31 | $131.60 Million | $3.09 Million | 0.024x | +109.70% |
| 2016-12-31 | $105.98 Million | $-25.69 Million | -0.242x | +44.75% |
| 2015-12-31 | $55.32 Million | $-24.27 Million | -0.439x | +37.17% |
| 2014-12-31 | $51.50 Million | $-35.96 Million | -0.698x | -552.28% |
| 2013-12-31 | $20.18 Million | $-2.16 Million | -0.107x | +99.78% |
| 2012-12-31 | $19.02K | $-908.54K | -47.770x | -- |